Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Convertible Debt (2018 - 2024)

Karyopharm Therapeutics (KPTI) has disclosed Convertible Debt for 7 consecutive years, with $171.1 million as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Convertible Debt changed 0.48% year-over-year to $171.1 million, compared with a TTM value of $171.1 million through Mar 2024, changed 0.48%, and an annual FY2023 reading of $170.9 million, changed 0.48% over the prior year.
  • Convertible Debt was $171.1 million for Q1 2024 at Karyopharm Therapeutics, roughly flat from $170.9 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $171.1 million in Q1 2024 and bottomed at $111.8 million in Q1 2020.
  • Average Convertible Debt over 5 years is $156.9 million, with a median of $169.5 million recorded in 2022.
  • The sharpest move saw Convertible Debt soared 50.94% in 2021, then increased 0.47% in 2022.
  • Year by year, Convertible Debt stood at $117.9 million in 2020, then soared by 43.56% to $169.3 million in 2021, then increased by 0.48% to $170.1 million in 2022, then grew by 0.48% to $170.9 million in 2023, then rose by 0.12% to $171.1 million in 2024.
  • Business Quant data shows Convertible Debt for KPTI at $171.1 million in Q1 2024, $170.9 million in Q4 2023, and $170.7 million in Q3 2023.